Awaiting development: Guidance and quality standards
Showing 1 to 10 of 341
Title | Type |
---|---|
.Net Upgrade Master test | Diagnostics guidance |
425 DGtest | Health technology evaluation |
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over TS ID 10679 | Technology appraisal guidance |
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095 | Technology appraisal guidance |
Abdominal aortic aneurysm | Quality standard |
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833] | Technology appraisal guidance |
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma TS ID 10553 | Technology appraisal guidance |
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia TS ID 11768 | Technology appraisal guidance |
Acne | Quality standard |
Adrenal dysfunction | Quality standard |